Nurix Therapeutics

Nurix team members are enjoying attending the Biotechnology Innovation Organization Convention. It's always a great time connecting with industry leaders, exploring groundbreaking innovations, and forging new partnerships that will shape the future of biotechnology. #BIO2024

Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m. ET. Listen to the live or archived presentation here: https://bit.ly/3yRXPZi

National Cancer Survivors Day is an annual, worldwide celebration to recognize cancer survivors, bring awareness to the ongoing challenges survivors face, and most importantly, celebrate life. At Nurix, we are developing novel therapies to potentially change the treatment landscape and increase the number of survivors of cancer. #NCSD #CancerSurvivorsDay

Nurix’s Research Associate of Analytical Chemistry, Shalya Masters, will present a poster presentation at the 36th International Symposium on Preparative and Process Chromatography taking place May 28-31, 2024. Learn more about the symposium here: https://www.prep2024.org/ #PREP2024

Nurix’s Senior Scientist of Analytical Chemistry, Amber Guillen, will present at the 36th International Symposium on Preparative and Process Chromatography on Thursday, May 30th at 3:00 p.m. ET. Learn more about the symposium here: https://www.prep2024.org/ #PREP2024

Congratulations to Nurix’s Vice President of Alliance & Research Project Management, Elizabeth Bosch, for being named as a finalist by the Association of Strategic Alliance Professionals as part of the 2024 ASAP Alliance Excellence Awards for exceptional innovation, leadership, and her contributions to alliance and partner excellence.     This recognition is a result of Elizabeth’s outstanding work on the ongoing research collaboration between Nurix and Gilead Sciences to develop novel targeted protein degraders, including IRAK4 degraders for the potential treatment of rheumatoid arthritis and other inflammatory diseases.  

We are excited to announce the election of board member Julia P. Gregory as the new chair of Nurix's board of directors. Her passion, extensive experience and strategic vision will be invaluable as we accelerate development of our drug programs with the goal of delivering life changing drugs for patients.   We’d also like to thank David L. Lacey, M.D., for his guidance and contributions as board chair over the last five years.   Read more about the board chair transition here: https://bit.ly/3WOeYNu

Today Nurix announced an upcoming oral presentation highlighting new clinical data from NX-5948, its orally available, selective BTK degrader, at the 2024 European Hematology Association (EHA) Congress. The presentation will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, including patients with BTK inhibitor resistance mutations and CNS involvement.  Learn more here: https://lnkd.in/geqT3Hm7 #EHA2024

Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET.     Listen to the live or archived discussion here: https://lnkd.in/gzJk762A

Nurix recently released its Annual Report highlighting company accomplishments and progress for the 2023 fiscal year. Included with the report is a letter to shareholders from CEO, Arthur T. Sands, M.D., Ph.D., where he summarizes 2023 advancements and discusses what’s to come in 2024. Read more in the full shareholder letter here: https://lnkd.in/gzbNRGa2